Results 51 to 60 of about 73,124 (298)

A Systematic Study of GelMA‐Carbopol Bioinks for High‐Fidelity Extrusion 3D Bioprinting at Physiological Temperatures

Advanced Healthcare Materials, EarlyView.
Gonzalez Martinez and collaborators develop a strategy to formulate high performance GelMA‐based bioinks with low solids contents. The resulting bioinks enable 3D bioprinting at 37 °C of high‐fidelity structures with tunable mechanical properties that support high cell viability and function.
David A. González‐Martínez, Aidee V. Arizpe Tafoya, Eduardo González‐Martínez, Mabel Barreiro Carpio, Laura Daniela Serrano Andrade, Christopher T. N. Chow, Mohammadhossein Dabaghi, Jeremy A. Hirota, Jose M. Moran‐Mirabal   +8 more
wiley   +1 more source

Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases [PDF]

Tuberculosis and Respiratory Diseases
Interstitial lung disease (ILD) comprises a heterogeneous group of disorders characterized by interstitial compartment proliferation, inflammatory infiltration, and potential fibrosis with abnormal collagen deposition.
Chul Park, Yoomi Yeo, A La Woo, Jung Wan Yoo, Goohyeon Hong, Jong Wook Shin, Sung Woo Park, on Behalf of the Korean Interstitial Lung Disease Study Group   +7 more
doaj   +1 more source

Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib

Respirology Case Reports, 2020
Nintedanib, a tyrosine kinase inhibitor, is approved for the treatment of idiopathic pulmonary fibrosis. We report a case of left ventricular dysfunction in a patient with idiopathic pulmonary fibrosis treated with nintedanib, which recovered after ...
Ryosuke Imai, Yutaka Tomishima
doaj   +1 more source

Efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial

Trials, 2022
Background and rationale Idiopathic pulmonary fibrosis is a critical disease with a poor prognosis. Although different studies have been conducted for the treatment of idiopathic pulmonary fibrosis, limited treatments are available.
Shu-guang Yang, Xue-qing Yu, Jian-sheng Li, Yang Xie, Wei Zhang, Chengjun Ban, Jihong Feng, Lei Wu, Xuechao Lu, Limin Zhao, Yong Meng, Miao Zhou, Yong He, Weixian Luo   +13 more
doaj   +1 more source

Pirfenidone in idiopathic pulmonary fibrosis [PDF]

European Respiratory Journal, 2009
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease without proven effective therapy. A multicentre, double-blind, placebo-controlled, randomised phase III clinical trial was conducted in Japanese patients with well-defined IPF to determine the efficacy and safety of pirfenidone, a novel antifibrotic
H, Taniguchi, M, Ebina, Y, Kondoh, T, Ogura, A, Azuma, M, Suga, Y, Taguchi, H, Takahashi, K, Nakata, A, Sato, M, Takeuchi, G, Raghu, S, Kudoh, T, Nukiwa   +13 more
openaire   +2 more sources

Idiopathic Pulmonary Fibrosis: Treatment and Prognosis

, 2015
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with a prognosis that can be worse than for many cancers. The initial stages of the condition were thought to mainly involve chronic inflammation; therefore, corticosteroids and ...
Tetsu Kobayashi, Hajime Fujimoto, Arata Azuma   +2 more
core   +1 more source

Perivascular Matrix Densification Dysregulates Angiogenesis and Activates Pro‐Inflammatory Endothelial Cells

Advanced Science, EarlyView.
Perivascular matrix densification promotes the emergence of aberrant endothelial tip cells (ATECs) that invade and persist within fibrotic microenvironments. Using in vivo lineage tracing and a human microvessel model, this study shows that fibrous matrix cues destabilize VE‐cadherin–mediated junctions to gate TGF‐β signaling, inducing a pro ...
Jingyi Xia, William Y. Wang, Kyle A. Jacobs, Kairav Maniar, Daphne Lin, Evan H. Jarman, Daniel L. Matera, Kristen Loesel, Christopher D. Davidson, Harrison L. Hiraki, Xiaotian Tan, Eve H. Shikanov, Robert N. Kent, Carole Parent, Xudong Fan, Ariella Shikanov, Matthew L. Kutys, Brendon M. Baker   +17 more
wiley   +1 more source

Identifying TNFSF4low-MSCs superiorly treating idiopathic pulmonary fibrosis through Tregs differentiation modulation

Stem Cell Research & Therapy
Background Idiopathic pulmonary fibrosis is a progressive lung disorder, presenting clinically with symptoms such as shortness of breath and hypoxemia. Despite its severe prognosis and limited treatment options, the pathogenesis of idiopathic pulmonary ...
Yuanyuan Xie, Qing Yi, Congwang Xu, Yaping Wang, Yue Jiang, Yirui Feng, Liudi Wang, Hui Yang, Yingwei Zhang, Bin Wang   +9 more
doaj   +1 more source

Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations

, 2015
Idiopathic pulmonary fibrosis (IPF) is a parenchymal lung disease characterized by progressive interstitial fibrosis. The clinical course of IPF can be unpredictable and may be punctuated by acute exacerbations.
Yutaro Nakamura, Takafumi Suda
core   +1 more source

Magnetic resonance imaging as a non-invasive tool to investigate pulmonary and renal fibrosis in small rodents : method and readout validation, animal model optimization, and substance testing [PDF]

, 2015
Pulmonary fibrosis, an end result of various types of lung damage including interstitial pneumonia and respiratory bronchiolitis (Gross and Hunninghake, 2001; Katzenstein and Myers, 1998; Lazenby et al., 1990) is a lethal disease characterized by ...
Egger, Christine
core   +1 more source